Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone

BACKGROUND: Myostatin antagonists are being developed as therapies for Duchenne muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered follistatin has the potential to combine the hypertrophy of myostatin antagonism with the anti-inflammatory and anti-fibrotic eff...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Skelet Muscle
Główni autorzy: Iskenderian, Andrea, Liu, Nan, Deng, Qingwei, Huang, Yan, Shen, Chuan, Palmieri, Kathleen, Crooker, Robert, Lundberg, Dianna, Kastrapeli, Niksa, Pescatore, Brian, Romashko, Alla, Dumas, John, Comeau, Robert, Norton, Angela, Pan, Jing, Rong, Haojing, Derakhchan, Katayoun, Ehmann, David E.
Format: Artigo
Język:Inglês
Wydane: BioMed Central 2018
Hasła przedmiotowe:
Research
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6204036/
https://ncbi.nlm.nih.gov/pubmed/30368252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13395-018-0180-z
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy